Immune Tolerance Induction in the Era of Emicizumab—Still the First Choice for Patients With Hemophilia A and Inhibitors?

Introduction: The development of inhibitory antibodies is a severe complication of clotting factor replacement therapy in patients with severe hemophilia A (HA). Current World Federation of Hemophilia guidelines for hemophilia care indicate that eradication of inhibitors is best achieved through immune tolerance induction (ITI) therapy.